1. Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.
- Author
-
Nemoto A, Inukai T, Uno K, Kiyokawa N, Miyagawa Y, Takahashi K, Sato H, Akahane K, Hirose K, Honna-Oshiro H, Goi K, Kagami K, Nakazawa S, Fujimoto J, Inaba T, and Sugita K
- Subjects
- Benzamides, Cell Line, Tumor, Cell Proliferation drug effects, Granulocyte Colony-Stimulating Factor pharmacology, Granulocyte-Macrophage Colony-Stimulating Factor pharmacology, Humans, Imatinib Mesylate, Interleukin-6 pharmacology, Leukemia genetics, Leukemia pathology, Antineoplastic Agents pharmacology, Intercellular Signaling Peptides and Proteins pharmacology, Leukemia drug therapy, Philadelphia Chromosome, Piperazines pharmacology, Pyrimidines pharmacology
- Abstract
Since BCR-ABL plays an essential role in the growth factor-independent proliferation of Philadelphia chromosome (Ph)+ leukemia cells, imatinib treatment of Ph+ leukemia cells inactivates signaling pathways of BCR-ABL, and subsequent addition of growth factors (GFs) could restore the signaling pathways without reactivating BCR-ABL. Here we demonstrated that non-lymphoid Ph+ leukemia cell lines responded to diverse GFs depending on their immunophenotype and gene expression of transcription factors and GF receptors, while lymphoid Ph+ leukemia cell lines restrictively responded to flit3 ligand and interleukin-7, suggesting that GF sensitivity of imatinib-treated Ph+ leukemia cells could be powerful for specifying their distinctive lineage., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF